Women ‘more likely to be told autoimmune conditions are psychological’

A Call for Clinical Clarity In October 2026, researchers at the University of Cambridge brought a vital conversation to the forefront of the United Kingdom’s health landscape. Their landmark study, published in the journal Rheumatology, sheds light on a systemic issue that has long persisted within medical corridors: the diagnostic gap between men and women facing autoimmune conditions. By analysing data from over 6,600 patients, the team has provided a much-needed evidence base that demands attention. This is not merely an academic exercise; it is a critical step toward ensuring that every patient, regardless of their gender, receives the accurate and timely care they deserve. For far too long, the journey to a diagnosis has been marred by inconsistencies, and this research finally offers the clarity needed to begin a new chapter in patient advocacy.

The Reality of Diagnostic Bias The findings revealed a sobering reality regarding how physical symptoms are perceived and categorized by healthcare providers. A psychosomatic misdiagnosis occurs when a patient’s genuine physical symptoms are incorrectly attributed to psychological factors, a situation that can lead to significant distress. The data suggests that women are significantly more likely to face this barrier than their male counterparts. Specifically, 43 per cent of female patients reported that their symptoms were misattributed to psychiatric causes, compared to 33 per cent of men. When researchers drilled down into the numbers, they found that women were nearly 75 per cent more likely than men to be told their autoimmune symptoms were psychological in origin. Even when the study accounted for complex variables like age, household finances, and the specific disease group involved, the gender disparity remained a constant and concerning factor. This bias creates a difficult environment for patients who are searching for answers about their own health, often leaving them without the medical support required to manage their conditions effectively.

Time as a Precious Resource One of the most striking differences identified by the Cambridge team relates to the duration of the diagnostic process. For many male patients involved in the study, the path to a formal diagnosis was relatively swift, with the most common timeframe from the onset of symptoms being less than three months. For women, however, the experience was vastly different. The most common timeframe for female patients to receive a diagnosis stretched from one to two years. This delay is more than a logistical hurdle; it is a profound burden. When physical health issues go undiagnosed, patients often suffer from secondary impacts, including higher levels of anxiety and depression. The emotional toll of being unheard or misunderstood during a time of physical pain cannot be overstated, and this study provides the objective data necessary to acknowledge that pain. By highlighting these time disparities, the researchers have effectively drawn a map for clinicians, pinpointing exactly where the system is failing to provide equitable care.

A Brighter Path Toward Trust The implications of this research extend far beyond the pages of a scientific journal. By identifying these systemic gaps, the University of Cambridge experts have offered a roadmap that, if followed, promises to reduce diagnostic delays and prevent the harm associated with misdiagnosis. The experts involved are clear: addressing these biases is an essential task for any healthcare system aiming to restore and maintain patient trust. It is a call to action for clinicians to consider autoimmune factors much earlier in the diagnostic process, ensuring that physical symptoms are investigated with the thoroughness they require. This research underscores the fundamental truth that biological sex and gender identity play a significant role in clinical outcomes. Moving forward, the focus must remain on educating professionals and utilizing this new clinical data to create a more responsive environment. There is a sense of optimism inherent in this work; by naming the problem and providing the evidence to support change, the medical community is now better equipped to prevent unnecessary suffering. As these findings permeate the UK health sector, the potential for faster, more accurate diagnoses becomes a tangible goal rather than a distant hope. For the thousands of patients currently navigating the complexities of autoimmune conditions, this study represents a powerful shift toward a future where every voice is heard, every symptom is taken seriously, and clinical care is truly inclusive.